A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Administered By

Awarded By

Contributors

Start/End

  • January 24, 2019 - December 31, 2023